Led by Daisy Robinton, PhD, Oviva aims to improve ovarian health and extend female healthspan through therapeutic innovation

April 2022 blog post by Cambrian CEO James Peyer, PhD

mTOR inhibitors prevent age-related physiologic decline and lengthen healthspan. Licensed compounds will be developed by new Cambrian subsidiary Tornado Therapeutics, led by Joan Mannick, M.D. as CEO.

January 2022 blog post by Cambrian CEO James Peyer, PhD

Financing co-led by Anthos Capital and SALT Fund; Anthos’s Paul Farr and biotech leader Brent Saunders to join Board of Directors.

Cambrian BioPharma Chief Operating Officer, Juliette Han, PhD named as one of the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report.

"Rational Mind", a science series hosted by engineer and influencer Pietro Boselli, aims to inspire viewers to use rationality and critical thinking to approach complex issues. In this episode, James discusses the longevity science space and the opportunities and challenges ahead.

James Peyer to present new research in the biology of aging at the world's largest aging research for drug discovery conference.

Does anyone really want to live until 180? Progress in longevity science is abundant at the moment, from healthspan hacking to novel therapies being brought under development. Our panel of experts discuss the philosophical and scientific innovations taking place at the cutting edge of the life-extensionists field and what implications they could have for us all.

Cambrian BioPharma is one of the newly emerging distributed drug discovery companies that applies a new twist to investing in interesting science. PM360 spoke with co-founder James Peyer about this new model, why he decided to focus on the biology of aging, and more.